Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Asfotase alfa price?

Asfotase alfa (Strensiq®) is an orphan‑drug biologic used to treat both infantile and adult forms of hypophosphatasia. Because it is a specialty drug for a very rare condition, its price is comparatively high and varies considerably by country, payer, and contractual arrangements. Below is a general snapshot of what you might expect in a few key markets—not a definitive or up‑to‑date billable amount for any specific patient or pharmacy.

Market Typical US list price (WAC) Typical European (EUR) Typical Canadian (CAD)
United States ≈ $2 – $4.5 million per year (based on 2018–2023 FDA pricing and CMS Medicare “average sales price” data) €1.2 – €1.8 million per year (average across France, Germany, UK, Italy) CAD 1.5 – 2.5 million per year (depending on province and pharmacy dispensing)

Key points to keep in mind:

  1. Dosing – Asfotase alfa is typically given by subcutaneous injection at a weight‑based dose of about 1 mg/kg every two weeks. The amount of drug needed per year is roughly 26–28 doses, which drives the cost.
  2. List price vs. net price – The figures above are “list” prices (i.e., the manufacturer’s advertised cost). Real‑world reimbursement (including rebates, discounts, or manufacturer discount programs) can bring the effective cost down by 10–30 % or more.
  3. Insurance coverage – In the U.S., Medicare Part D (and in many private plans) will cover most of the cost after a patient’s deductible has been met. For many patients, the out‑of‑pocket expense is a modest copay or coinsurance, not the full list price.
  4. Specialty pharmacy programs – Many patients enroll in a manufacturer‑supported “patient assistance” or “access program” that can reduce or even eliminate the copay for the first few months of therapy, especially if the patient meets specific eligibility criteria (e.g., low income, no insurance coverage).
  5. International differences – Pricing can be lower in some European countries where national health authorities negotiate prices directly with the manufacturer. In other jurisdictions (e.g., certain Asian or Latin American countries), the drug may not yet be reimbursed, so patients must pay out‑of‑pocket unless they qualify for a special grant or assistance program.

How the price is determined

  • Orphan drug status: The FDA and EMA grant special pricing and market exclusivity to drugs treating rare diseases. This can justify a higher list price due to the smaller patient population and higher research and development costs.
  • Cost of manufacturing: Asfotase alfa is a recombinant enzyme produced in mammalian cell culture, which is labor‑intensive and costly.
  • Regulatory and development costs: The drug has undergone extensive clinical trials; those costs are reflected in the final price.
  • Market dynamics: Because there are few competitors for a rare‑disease therapy, the manufacturer has pricing power.

What you can do if you’re facing the cost

  1. Check your insurance policy: Ask whether the drug is on the formulary and what the copay/coinsurance will be after the deductible.
  2. Ask about manufacturer assistance: Strensiq® offers a patient support program; eligibility is based on income, insurance status, and other criteria.
  3. Speak with a pharmacist or financial counselor: Many specialty pharmacies have financial advisors who can help you navigate rebates, coupons, and payment plans.
  4. Explore clinical trials: If you’re eligible, enrolling in a study may provide access to the drug at reduced or no cost.

Disclaimer: Prices change frequently due to negotiations, policy updates, and changes in insurance coverage. The numbers above are approximate and should be verified with your insurer, pharmacist, or the manufacturer’s most recent data.



Other Questions About Asfotase :

Asfotase alfa (strensiq) biosimilar?